Novo’s Tresiba primed for key ‘hypo’ label update in EU
Fast-acting insulin also approved in US
X
Novo’s Tresiba primed for key ‘hypo’ label update in EU
https://pharmaphorum.com/news/novos-tresiba-gets-key-hypo-label-update-eu/
Novo Nordisk
No cardio protection indication for Novo’s semaglutide – yet
Danish pharma plans outcome trial to confirm benefits in SUSTAIN 6
Novo aims for GLP-1 sales growth in China
Novo expects Victoza and semaglutide to gain momentum.
Pharma 2022: big pharma will remain a constant
Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.
Novo highlights key ‘hypo’ data from Tresiba at EASD
Novo hopes data will justify higher price compared with rival.
Novo showcases next-gen GLP-1 at EASD
Semaglutide is under review in Europe and US.
Teva appoints Lundbeck’s Kare Schultz as CEO
Unlike AZ’s Soriot, Schultz “couldn’t refuse” top job at Teva.